Last reviewed · How we verify

perindopril + moxonidine — Competitive Intelligence Brief

perindopril + moxonidine (perindopril + moxonidine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor + imidazoline receptor agonist combination. Area: Cardiovascular.

marketed ACE inhibitor + imidazoline receptor agonist combination ACE (angiotensin-converting enzyme) and imidazoline-1 receptors Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

perindopril + moxonidine (perindopril + moxonidine) — Sergey V. Nedogoda. Perindopril inhibits ACE to reduce angiotensin II formation, while moxonidine activates central imidazoline receptors to reduce sympathetic outflow, together lowering blood pressure through complementary pathways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
perindopril + moxonidine TARGET perindopril + moxonidine Sergey V. Nedogoda marketed ACE inhibitor + imidazoline receptor agonist combination ACE (angiotensin-converting enzyme) and imidazoline-1 receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor + imidazoline receptor agonist combination class)

  1. Sergey V. Nedogoda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). perindopril + moxonidine — Competitive Intelligence Brief. https://druglandscape.com/ci/perindopril-moxonidine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: